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Abstract
Background: The mechanisms underlying neurotoxicity caused by L-DOPA are not yet completely known. Based on recent
findings, we speculated that the increased expression of divalent metal transporter 1 without iron-response element
(DMT12IRE) induced by L-DOPA might play a critical role in the development of L-DOPA neurotoxicity. To test this
hypothesis, we investigated the effects of astrocyte-conditioned medium (ACM) and siRNA DMT-IRE on L-DOPA
neurotoxicity in cortical neurons.
Methods and Findings: We demonstrated that neurons treated with L-DOPA have a significant dose-dependent decrease in
neuronal viability (MTT Assay) and increase in iron content (using a graphite furnace atomic absorption spectrophotometer),
DMT12IRE expression (Western blot analysis) and ferrous iron (55Fe(II)) uptake. Neurons incubated in ACM with or without
L-DOPA had no significant differences in their morphology, Hoechst-33342 staining or viability. Also, ACM significantly
inhibited the effects of L-DOPA on neuronal iron content as well as DMT12IRE expression. In addition, we demonstrated
that infection of neurons with siRNA DMT-IRE led to a significant decrease in DMT12IRE expression as well as L-DOPA
neurotoxicity.
Conclusion: The up-regulation of DMT12IRE and the increase in DMT12IRE-mediated iron influx play a key role in L-DOPA
neurotoxicity in cortical neurons.
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder that affects approximately 1% of the people over the age
of 60 [1]. This disorder is mainly characterized by the
degeneration of dopamine-containing neurons in the substrantia
nigra. This brain section is therefore deprived of adequate
amounts of the neurotransmitter dopamine [2]. Because dopamine
is unable to access the brain directly, L-3,4-dihydroxyphenylala-
nine (L-DOPA), its natural precursor, is used in clinical treatment
of patients with PD. Until now, L-DOPA remains the most
effective drug for the symptomatic control of PD [3,4]. However,
accumulated evidence shows that the therapeutic efficacy of L-
DOPA is gradually lost over time, and abnormal involuntary
movements, dyskinesias, gradually emerge as a prominent side
effect of the previously beneficial doses of the drug [5–7].
The precise molecular mechanisms underlying the neurotoxicity
caused by L-DOPA are not yet completely known. Available data
suggest that L-DOPA might have the ability to significantly affect
iron distribution in the brain. The changes in brain iron
distribution induced by L-DOPA might be one of the causes of
the neurotoxicity of L-DOPA. A clinical study [8] demonstrated
that L-DOPA could significantly affect brain ceruloplasmin (CP), a
major factor in the regulation of regional brain iron, and that L-
DOPA-treated PD patients had a significantly higher CP than
those who were not given L-DOPA. A pathological study of
postmortem brain tissue showed that the levels of iron storage
protein ferritin were significantly lower in several brain regions of
PD patients treated with L-DOPA than those in the age-matched
control patients [9]. In a recent study, we demonstrated that L-
DOPA induces a significant increase in the expression of divalent
metal transporter 1 without iron-response element (DMT12IRE),
but not divalent metal transporter 1 with iron-response element
(DMT1+IRE), TfR1 or Fpn1, and a remarkable increase in
ferrous uptake in cells [10].
Based on these findings, plus the potential role of DMT12IRE
in neuronal iron uptake and the implication of iron as a major
generator of reactive oxygen species, we speculated that the
upregulation of DMT12IRE might play a critical role in the
development of L-DOPA neurotoxicity. L-DOPA might have a
role to increase DMT12IRE expression, which in turn leads to a
remarkable increase in DMT12IRE-mediated ferrous iron uptake
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generates highly reactive hydroxyl radicals via the Fenton reaction
or Haber-Weiss reaction. In turn, these free radicals can damage
the biological molecules of neurons, leading to the development of
L-DOPA neurotoxicity. To test this hypothesis, we investigated the
effects of astrocyte-conditioned medium (ACM) and siRNA
DMT2IRE on L-DOPA neurotoxicity by observing the changes
in morphology and Hoechst 33342 staining, measuring neuronal
viability, neuronal iron content, expression of DMT12IRE,
DMT1+IRE, TfR1 and Fpn1 proteins and ferrous iron uptake
in cortical neurons in the present study. Our results provide solid
evidence that the upregulation of DMT12IRE plays a key role in
the development of L-DOPA neurotoxicity in vitro. The findings
imply that inhibition of DMT12IRE expression or neuronal iron
uptake might be an effective approach to prevent or delay the
development of L-DOPA neurotoxicity in PD patients.
Materials and Methods
Materials
Unless otherwise stated, all chemicals were obtained from
Sigma Chemical Company, St. Louis, MO, USA. The scintillation
cocktail and tubes were purchased from Beckman Coulter
Company, Fullerton, CA, USA and
55FeCl3 from Perkinelmer
Company, Wellesley, MA, USA. The antibodies against
DMT1+IRE, DMT12IRE and Fpn1 were purchased from Alpha
Diagnostic International Company, San Antonio, TX, USA and
mouse anti-rat TfR1 monoclonal antibody was obtained from BD
Transduction Laboratories, BD Biosciences Pharmingen, USA.
The specific antibodies against neuron microtubule-associated
protein 2 (MAP2) and astrocyte glial fibrillary acadic protein
(GFAP) were purchased from Chemicon International Ltd, UK
and Hoechst 33342 from Polysciences Inc., Warrington, PA, USA.
Primary cortical neurons
Primary cortical neurons were prepared from embryonic Day
18 (E18) rats as previously described [11] with minor modifica-
tions. The purity of these cultures was assessed by staining for the
neuron specific antibodies against MAP2 and the astrocyte marker
GFAP.
Preparation of astrocytes culture medium
Primary astrocytes were prepared as previously described
[12,13]. The purity of astrocyte cultures was determined using
anti-GFAP antibody. The medium was changed to DMEM/F12
supplemented with 2% newborn calf serum (NCS), collected
48 hours later (astrocyte conditioned medium, ACM), centrifuged
at 3000 r/min for 15 min to remove cellular debris and then
stored at 280uC.
Experimental Design
To investigate the effects of L-DOPA on cortical neurons, the
cells were treated with different concentrations of L-DOPA (0, 1,
5, 10, 100 or 200 mM) in DMEM+5%FBS for 16 hours and then
morphological changes, neuronal viability, cell iron content, the
expression of DMT12IRE, DMT1+IRE, TfR1 and Fpn1
proteins and NTBI (non-transferrin bound iron) uptake were
determined. To detect the effects of ACM on the neurotoxicity
induced by L-DOPA, neurons were incubated with or without L-
DOPA in DMEM+5%FBS or ACM for 16 hours followed by the
relevant measurements. To further confirm whether the increased
expression of DMT12IRE was involved in the neurotoxicity
induced by L-DOPA, neurons were pre-incubated with siRNA
DMT12IRE for 24 hours before treatment with L-DOPA.
Morphological observation
Morphological changes of the neurons were observed under
phase contrast microscopy or fluorescence microscopy.
Determination of cell viability
ThecellviabilitywasdeterminedusinganMTTassayasdescribed
previously[14,15].Opticaldensity(OD)wasmeasuredat570 nmby
the use of the ELX-800 microplate assay reader (Bio-tek, USA).
Immunocytochemistry
Immunocytochemical experiments were performed using neu-
ron specific mouse anti-MAP2, astrocyte specific anti-GFAP,
rabbit anti-rat DMT12IRE, DMT1+IRE, TfR1 and rabbit anti-
mouse Fpn1 antibodies respectively [16]. Cortical neurons in slides
were incubated with one of the above antibodies: anti-MAP2
(1:200), anti-GFAP (1:200), anti-rat DMT12IRE (1:500),
DMT1+IRE (1:500), TfR (1:200) and anti-mouse Fpn1 (1:500)
for 24 hours, followed by FITC-labeled goat anti-mouse IgG
(1:200), or Rhodamine-labeled goat anti-rabbit IgG (1:200)
(Invitrogen, USA) as the secondary antibody. Fluorescent images
were captured by using a Nikon Eclipse TE2000-U microscope
(Nikon, UK) equipped with T-FL Epi-FI attachment and a SPOT
cooled CCD camera (Diagnostic Instruments, INC, US). SPOT
software version 4.6 was used for image acquisition (Diagnostic
Instruments, INC, US).
Hoechst 33342 staining
Hoechst 33342 staining was used to detect morphological
features of apoptotic cell death. Cortical neurons pre-treated with
or without different concentrations of L-DOPA were stained with
Hoechst 33342. The cells were then examined under a fluorescent
microscope. Undamaged cell nuclei were large and diffusely
stained whereas apoptotic nuclei showed chromatin that was
condensed and fragmented.
Iron measurement
The slides were fixed with 4% paraformalin for 10 min. After
three washes with PBS, the slides were incubated in Perl’s solution
containing 4% potassiumferrocanide and an equal volume of
1.2 mmol/L hydrochloride acid solution for 16 hours at 4uC and
then washed with deionized water 3 times, followed by
dehydration through 95% alcohol and mounting with xylene.
Iron staining was observed under a Nikon Eclipse TE2000-U
microscope (Nikon, UK). The total iron in the neurons was also
determined using a graphite furnace atomic absorption spectro-
photometer (GFAAS, Perkin Elmer, Analyst 100) as previously
described [17,18].
Western blot analysis
Neurons that received different treatments were washed with
ice-cold PBS, homogenized with lysis buffer and then subjected to
sonication using Soniprep 150 (MSE Scientific Instruments,
London, UK). After centrifugation at 10,000 g for 15 min at
4uC, the supernatant was collected, and protein content was
determined using the Bradford assay kit (Bio-Rad). Aliquots of the
cell extract containing 30 mg of protein were diluted in 2 ml sample
buffer (50 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 0.1%
bromphenol blue, and 5% b-mercaptoethanol) and heated for
5 min at 95uC before SDS-PAGE on 10% gel and subsequently
transferred to a pure nitrocellulose membrane. After the transfer,
the membrane was blocked with 5% blocking reagent in Tris-
buffered saline containing 0.1% Tween-20 overnight at 4uC. The
membrane was rinsed in three changes of Tris-buffered saline/
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twice for 5 min, and then incubated overnight at 4uC with
primary antibodies: rabbit anti-rat DMT1+IRE, DMT12IRE
polyclonal antibodies, rabbit anti-mouse Fpn1 polyclonal antibody
(1:5000); mouse anti-rat TfR1 monoclonal antibody (1:1000).
After three washes, the blots were incubated with goat anti-rabbit
or anti-mouse IRDye 800 CW secondary antibody (1:5000, Li-
Cor) for 1 hour at room temperature. The intensity of the specific
bands was detected and analyzed by Odyssey infrared imagine
system (Li-Cor). To ensure even loading of the samples, the same
membrane was probed with rabbit anti-rat b-actin polyclonal
antibody at a 1:2000 dilution.
Construction of siRNA against DMT-IRE
pSUPER.retro vector (OligoEngine, USA) was used for
expression of siRNA targeting on DMT12IRE. The target sites
for siRNA were designed by using an oligoEngine tool. The
selected sequences were submitted to a BLAST search to avoid
targeting the other human genome. Two 19-nucleotide sequences
corresponding to nucleotides 1681–1699 and 1776–1794 of
DMT12IRE were selected to generate the pSUPER-hepcidin
vectors. A control vector (pSUPER-Control) was constructed using
a 19-nucleotide sequence (gcgcgctttgtaggattcg) with no significant
homology to any mammalian gene sequence and therefore served
as a non-silencing control (OligoEngine, USA). These sequences
were inserted into the pSUPER.retro vector after digestion with
BglII and HindIII and were transformed into BL21-A1 One
ShotTM supercompetent cells (Invitrogen, USA). Several clones
were obtained, and the vectors were amplified. Retroviruses
expressing siRNA DMT12IRE were produced by transfecting
pSUPER-hepcidin vectors into amphotropic Phoenix packaging
cell line according to the manufacturer’s instructions. The
obtained retrovirus was used to the in vitro infection of cells or
in vivo injection of cerebroventricules.
Measurement of non-transferrin bound iron uptake
The radio-labelled 55Fe(II) (NTBI) solution was prepared and
the Fe(II) uptake was measured as described previously [19].
Following pre-treatment with different concentrations of L-
DOPA, the cells were washed with cold PBS and then incubated
with or without 55Fe(II) for various periods of time. After being
lysed, the cells were scraped off and transferred into Eppendorf
tubes. A 50 ml aliquot was subjected to the detection of protein
concentration. The cytosol was separated from the stromal
fraction by centrifugation at 10,000 g for 20 min at 4uC using a
Jouan centrifuge (DJB labcare Ltd., England). Scintillation
solution (3 ml) was added to count the cpm. The total iron uptake
was the sum of the cytosol and stromal fractions.
Statistical analysis
Statistical analyses were performed using SPSS software for
Windows (version 10.0). Data were presented as mean6SEM. The
difference between the means was determined by One-Way
ANOVA followed by a Student-Newman-Keuls test for multiple
comparisons. A probability value of P,0.05 was taken to be
statistically significant.
Figure 1. L–DOPA induced morphological changes in cortical
neurons. Neurons were treated with L-DOPA (0, 1, 5, 10, 100, 200 mM)
in DMEM+5%FBS (A) or astrocyte-conditioned medium (ACM) (B) for
16 hours and then morphological changes were observed as described
in Materials and Methods.
doi:10.1371/journal.pone.0004593.g001
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Neurotoxicity induced by L-DOPA: morphological
evidence and significantly decreased neuronal viability
Figure 1A presented the morphological observations in neurons
treated with L-DOPA (0, 1, 5, 10, 100 or 200 mM) in
DMEM+5%FBS for 16 hours. As compared to the controls,
neurons pre-treated with L-DOPA displayed a dose-dependent
morphological change. It was characterized by a progressive
increase in the number of irregular cell bodies with disrupted and
shrunken neuronal processes with the increase in the concentra-
tions of L-DOPA in the medium. Pre-treatment with 200 mMo f
L-DOPA induced a significant reduction in or disappearance of
the neuronal number or processes. The observations under phase
contrast microscopy corresponded to the findings of immuno-
staining of cortical neurons for MAP2 (Figure 2A). Hoechst 33342
staining (Figure 3A) displayed a gradual increase in the number of
condensed or fragmented nuclei (apoptosis) in cortical cells with
the increase in the concentrations of L-DOPA. The number of
condensed nuclei was the highest in the neurons pretreated with
200 mM of L-DOPA. The neuronal viability was determined using
an MTT assay. As shown in Figure 4A, treatment of neurons with
L-DOPA in DMEM+5%FBS for 16 hours led to a progressive
decrease in the cell viability with the increase in the concentrations
of L-DOPA. A significant decrease in viability was found in the
neurons treated with 10, 100 or 200 mM of L-DOPA (P,0.01 or
0.001).
ACM diminishes L-DOPA-induced neurotoxicity
Treatment with L-DOPA did not induce any significant
changes in neuronal morphology or the immunostaining of
cortical neurons for MAP2 when the incubation medium
DMEM+5%FBS was replaced by ACM. No significant differences
in cell morphology (Figure 1B) or the MAP2 (Figure 2B) were
found among the neurons treated with or without different
concentrations of L-DOPA. Consistent with this observation,
Hoechst 33342 staining demonstrated that cell nuclei remained
unchanged in neurons that were incubated with 200 mMo fL -
DOPA in ACM (Figure 3B). No significant differences in Hoechst
33342 staining were found between the neurons treated with or
without 200 mM of L-DOPA in ACM. Furthermore, cell viabilities
in the neurons that were incubated with 10, 100 or 200 mMo fL -
DOPA in ACM were significantly higher than those in the
neurons incubated with same concentrations of L-DOPA in
DMEM+5%FBS medium (P,0.001 or 0.0001) (Figure 4B).
L-DOPA induces a significant increase in iron content in
cortical neurons
Figure 5A presented the data on iron stain in neurons that were
treated with different concentrations of L-DOPA in
DMEM+5%FBS for 16 hours. The control neurons had large
cell bodies and more elaborate processes with a tiny amount of
iron located primarily in the cell bodies. No changes in iron
distribution and morphology were found in neurons pre-treated
with 1 mM of L-DOPA. In the neurons treated with 5 mMo fL -
DOPA, iron content in the cell body appeared to have increased
but the body shape and body size remained the same. A significant
Figure 2. Immunocytochemistry of MAP2 in cortical neurons
treated with or without L-DOPA. Neurons were exposed to L-DOPA
(0, 1, 5, 10, 100, 200 mM) in DMEM+5%FBS (A) or astrocyte-conditioned
medium (ACM) (B) for 16 hours and then immunostained for MAP-2
antibody as described in Materials and Methods.
doi:10.1371/journal.pone.0004593.g002
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was observed in the neurons treated with 10, 100 or 200 mMo fL -
DOPA. The iron accumulation was most pronounced in neurons
pre-treated with 200 mM of L-DOPA, which appeared dystrophic
with large and irregularly-shaped cell bodies attaching to densely
beaded processes and the iron filling the cell body and processes
completely. The measurement of total iron provided quantitative
evidence for the ability of L-DOPA to induce a significant increase
in neuronal iron contents. The total iron was significantly higher in
neurons pretreated with 5, 10, 100 or 200 mM of L-DOPA than in
the controls (Figure 5C).
ACM reduces iron content in cortical neuron treated with
L-DOPA
Figure 5B presented the data on iron stain in neurons that were
treated with different concentrations of L-DOPA in ACM. No
significant changes in neuron iron contents were observed when
Figure 3. Hoechst 33342 staining in cortical neurons treated
with or without L-DOPA. Neurons were exposed to 0, 1, 5, 10, 100 or
200 mM of L-DOPA in DMEM+5%FBS (A) or 0 or 200 mM of L-DOPA in
astrocyte-conditioned medium (ACM) (B) for 16 hours and then
Hoechst 33342 staining was performed. The nuclei with fluorescing
intensely, shrunken in size and irregular in shape are indicated in arrows.
doi:10.1371/journal.pone.0004593.g003
Figure 4. Effects of L-DOPA on neuronal viability. Neurons were
treated with 0, 1, 5, 10, 100 or 200 mM of L-DOPA in DMEM+5%FBS for
16 hours (A) or incubated with 0, 10, 100 or 200 mM of L-DOPA in
DMEM +5%FBS medium (L-DOPA) or astrocyte-conditioned medium (L-
DOPA+ACM) for 16 hours (B). The neuronal viability was then
determined using an MTT assay. Data are the mean6SEM (percentage
of control) of three independent experiments performed in triplicate. A:
*P,0.01, **P,0.001, vs. the control (0 mM). B: **P,0.001, ***P,0.0001
vs. the corresponding controls.
doi:10.1371/journal.pone.0004593.g004
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200 mM) for 16 hours (Figures 5B). Treatment with ACM induced
a significant decrease in iron content in cortical neurons treated
with 200 mM of L-DOPA (Figure 5C). These results demonstrated
that ACM has the ability to inhibit the effect of L-DOPA on iron
content in cortical neurons.
Figure 5. Effects of L-DOPA on neuronal iron. Neurons were exposed to L-DOPA (0, 1, 5, 10, 100, 200 mM) in DMEM+5%FBS (A) or astrocyte-
conditioned medium (ACM) (B) for 16 hours and then iron staining was conducted. Total iron was also measured using a GFAAS method in the
neurons treated with or without different concentrations of L-DOPA in the presence or absence of ACM (C). Data are the mean6SEM (percentage of
control) of three independent experiments performed in triplicate. *P,0.05, **P,0.01 vs. the control (0 mM); #,0.01 vs. 200 mM of L-DOPA.
doi:10.1371/journal.pone.0004593.g005
Figure 6. Effects of L-DOPA on the expression of DMT12IRE, DMT1+IRE, Fpn1 and TfR1 proteins in cortical neurons. Neurons were
treated with L-DOPA (0, 1, 5, 10, 100, 200 mM) in DMEM+5%FBS for 16 hours and the expression of proteins was determined using Western blot
analysis. A, representative Western blots of DMT12IRE and b-actin. B, the relative values of DMT12IRE protein expression. C, representative Western
blots of DMT1+IRE and b-actin. D, the relative values of DMT1+IRE protein expression. E, representative Western blots of Fpn1 and b-actin. F, the
relative values of Fpn1 protein expression. G, representative Western blots of TfR1 and b-actin. H, the relative values of TfR1 protein expression. Data
are means6SEM (percentage of control) of four independent experiments. L-DOPA treatment induced a dose-dependent decrease in TfR. There were
no significant differences in the levels of DMT1+IRE and Fpn1 protein between neurons treated with and without L-DOPA. * P,0.05, ** P,0.01 vs. the
control.
doi:10.1371/journal.pone.0004593.g006
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expression and ferrous iron uptake in cortical neurons
L-DOPA treatment induced a significant and dose-dependent
increase in the expression of DMT12IRE (Figures 6A,B). The
levels of DMT12IRE in the neurons pre-treated with 5, 10, 100
or 200 mM of L-DOPA were significantly higher than those in the
controls (P,0.05 or 0.01). The results from immunostaining of
DMT1 also indicated that L-DOPA has a significant ability to
increase the expression of DMT12IRE rather than DMT1+IRE
in cortical neurons (Figure 7A). However, treatment of cortical
neurons with L-DOPA did not induce any changes in the
expression of DMT1+IRE (Figures 6C,D and Figure 7B) or Fpn1
(Figures 6E,F and Figure 7C). This implies that the increased iron
contents in the neurons pre-treated with L-DOPA are associated
neither with DMT1+IRE nor the decreased Fpn1-mediated iron
release from the cells. Western blot analysis also demonstrated that
treatment with L-DOPA induces a dose-dependent decrease in
TfR1 (Figures 6G,H and Figure 7D), rather than an increase as we
expected. This shows that TfR1 is not involved in the increased
neuronal iron contents induced by L-DOPA.
These findings led us to hypothesize that the increased
DMT12IRE expression might induce an increase in
DMT12IRE-mediated ferrous iron uptake by neurons. This
might be one of the reasons for the L-DOPA-induced increase in
neuronal iron contents. Therefore, we then examined effects of L-
DOPA on ferrous iron uptake in neurons. As shown in Figure 8,
treatment with L-DOPA induced a significant and dose-dependent
increase in the 55Fe uptake by neurons. The 55Fe uptake was
significantly higher in the neurons pre-treated with 5, 10, 100 or
200 mM of L-DOPA than those in the controls (P,0.05 or 0.01).
Correlation analysis of the relationship between the expression of
DMT12IRE protein and the 55Fe uptake in the neurons was
conducted by plotting the values for these two indicators against
one another. A highly significant correlation was found in the cells
pre-treated with different concentrations of L-DOPA
(Y=0.924x+11.603, R2=0.974, P,0.001). The relationship
between the expression of DMT12IRE protein and neuronal
viability was also determined by the same analysis. A highly
significant correlation was also found in the cells pre-treated with
different concentrations of L-DOPA (Y=20.7165x+178.28,
R2=0.853, P,0.01).
ACM reduces DMT12IRE expression in cortical neuron
treated with L-DOPA
No significant differences were found in the expression of
DMT12IRE (Figures 9A,B) or other iron transport proteins
including DMT1+IRE (Figures 9C,D), Fpn1 (Figures 9E,F) and
TfR1 (Figures 9G,H) among the neurons incubated in ACM with
0, 100 or 200 mM of L-DOPA. The data imply that ACM has a
role to inhibit the increased expression of DMT12IRE induced by
L-DOPA in cortical neurons. Although we did not measure
ferrous iron uptake in the cortical neurons treated with 0, 100 or
200 mM of L-DOPA in the ACM media, it is reasonable to believe
that ACM also has the ability to inhibit the increased ferrous iron
uptake induced by L-DOPA in cortical neurons. Thus, the
significant role of ACM in protecting cortical neurons from L-
DOPA toxicity is ‘‘DMT12IRE and iron’’-mediated. To find out
whether antioxidant has the same effect as ACM, we also
investigated the effects of antioxidant on L-DOPA induced-
neurotoxicity by the addition of different doses of superoxide
dismutase (SOD) to the neuron culture medium. It was found that
SOD has a significant role to protect neurons from L-DOPA-
induced injury (data not shown) which suggested that the
neuroprotective role of ACM is also partly associated with its
antioxidative acticity which might be due to the antioxidants
supplied by astrocytes.
Decreased expression of DMT12IRE induced by siRNA
DMT-IRE reduces L-DOPA neurotoxicity
We then investigated the effects of siRNA DMT2IRE on
DMT12IRE expression and L-DOPA-induced neurontoxicity in
cortical neurons. Incubation of neurons with siRNA DMT2IRE
for 24 hours induced a significant decrease in the expression level
of DMT12IRE protein in the infected neurons (Figures 10A and
B). When neurons were pre-incubated with siRNA DMT2IRE
for 24 hours and then treated with different concentrations of L-
DOPA for 16 hours, it was found that the viabilities of the neurons
infected with ‘siRNA DMT2IRE’ were significantly higher than
those of the control neurons at 10, 100 or 200 mg of L-DOPA
(p,0.05, 0.01 or 0.01) (Figure 10C). The findings demonstrated
that the decreased expression of DMT12IRE induced by siRNA
DMT2IRE can reduce L-DOPA neurotoxicity.
Discussion
The exact etiology of the neurotoxicity induced by L-DOPA is
unknown although there is evidence that abnormal pulsatile
stimulation of dopamine receptors may be contributory to it
[20,21]. Based on our recent findings [10], together with the
potential role of DMT12IRE in neuronal iron uptake [10,22] and
Figure 7. Immmocytochemistry of DMT12IRE, DMT1+IRE, Fpn1 and TfR1 proteins in cortical neurons. Cells were treated with L-DOPA
(0, 1, 5, 10, 100, 200 mM) in DMEM+5%FBS for 16 hours and then immunostained for DMT12IRE (A), DMT1+IRE (B), Fpn1 (C) or TfR1 (D) antibodies. L-
DOPA treatment induced a dose-dependent decrease in TfR1 expression, but no significant changes were observed in the expression of DMT1+IRE
and Fpn1 proteins.
doi:10.1371/journal.pone.0004593.g007
Figure 8. Effects of L-DOPA on 55Fe(II) uptake by cortical cells.
Neurons were treated with L-DOPA (0, 1, 5, 10, 100, 200 mM) in
DMEM+5%FBS for 16 hours and then incubated with 2 mM of 55Fe(II) in
0.27 M sucrose (pH 6.5) at 37uC for 30 min. The 55Fe(II) taken into
neurons was then measured. Data were presented as mean6SEM of 6
independent experiments performed in triplicate. *P,0.05, **P,0.01
vs. the control.
doi:10.1371/journal.pone.0004593.g008
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neurons treated with L-DOPA. Neurons were treated with L-DOPA (0, 100 or 200 mM) in ACM for 16 hours and Western blot analysis was then
conducted. A, representative Western blots of DMT12IRE and b-actin. B, the relative values of DMT12IRE protein expression. C, representative
Western blots of DMT1+IRE and b-actin. D, the relative values of DMT1+IRE protein expression. E, representative Western blots of Fpn1 and b-actin. F,
the relative values of Fpn1 protein expression. G, representative Western blots of TfR1 and b-actin. H, the relative values of TfR1 protein expression.
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oxygen species, we hypothesized that the upregulation of
DMT12IRE might play a critical role in the development of L-
DOPA neurotoxicity. In the present study, efforts were made to
test this hypothesis. Based on several lines of solid evidence
obtained from this study, we concluded that the L-DOPA-induced
neurotoxicity is mediated by the upregulation of DMT12IRE
expression in cortical neurons.
The first evidence comes from the investigation of the effects of L-
DOPA on cortical neurons. Our data clearly demonstrated that
treating neurons with different concentrations of L-DOPA induces
not only a significant change in morphology or Hoechst-33342
staining but also a dose-dependent decrease in neuronal viability,
confirming that L-DOPA can induce neurotoxicity in our
experimental conditions. Meanwhile, the treatment also resulted in
a significant dose-dependent increase in iron content, ferrous iron
uptake and DMT12IRE protein expression in cortical neurons.
Furthermore, correlation analysis showed that the expression of
DMT12IRE protein is significantly correlated with 55Fe uptake
(positively) and neuronal viability (negatively) in cortical neurons
treated with different concentrations of L-DOPA; respectively.
These findings support a role of L-DOPA in the increased
DMT12IRE expression aswell asinthe connection oftheincreased
DMT12IRE with the increased neuron iron content. In addition,
bothwestern blot andimmunocytochemistryanalysisshowed thatL-
DOPA didn’t induce any changes in the expression of DMT1+IRE
or Fpn1. A significant decrease in TfR1 expression, rather than an
increase, was found in the neurons treated with L-DOPA. These
results showed that the increase in neuronal iron content induced by
L-DOPA is due to neither the decrease in Fpn1-mediated iron efflux
nor the increase in DMT1+IRE or TfR1-mediated iron uptake. On
the other hand, these results also provided further support that L-
DOPA has a role to increase DMT12IRE expression and that the
increased iron content in neurons induced by L-DOPA results from
the increased DMT12IRE-mediated iron uptake.
The second evidence is obtained from the study on the effects of
ACM on L-DOPA-induced neurotoxicity. It has been reported
that astrocytes have a role in the reduction of neuronal cell death
following a variety of cellular stresses, such as excitotoxicity and
oxidative stress [23–25]. Also, it has been demonstrated that glia
conditioned medium (GCM) protects fetal rat midbrain neurons in
culture from L-DOPA toxicity [26]. We speculated that the
neuroprotective role of GCM or ACM might be mediated by their
ability to inhibit DMT12IRE expression as well as iron
accumulation in neurons. Therefore, we investigated the effects
of ACM on morphology, Hoechst 33342 staining, viability, neuron
iron content and DMT12IRE expression in the neurons treated
with L-DOPA by incubating neurons in ACM with or without
different concentrations of L-DOPA for 16 hours. The results
obtained on the morphology, Hoechst 33342 staining and
neuronal viability clearly demonstrated that ACM significantly
diminishes L-DOPA-induced neurotoxicity. No significant differ-
ences were found in morphology, Hoechst-33342 staining and
viability between the neurons incubated in ACM in the presence
and those incubated in ACM in the absence of the same
concentrations of L-DOPA. At the same time, western blot
analysis and iron staining showed that ACM significantly reduces
DMT12IRE expression as well as neuron iron content. The
similar tendencies of the effects of ACM on L-DOPA-induced
neurotoxicity, DMT12IRE expression and neuron iron content
implied that ACM protects neurons from L-DOPA by its ability to
inhibit DMT12IRE expression and ferrous iron uptake.
The final piece of evidence is provided by the data on the effects
of siRNA DMT2IRE on L-DOPA neurotoxicity. According to
the findings on DMT12IRE, L-DOPA neurotoxicity and the role
of ACM, we expected that a decrease in DMT12IRE expression
should also be able to lead to a decrease in L-DOPA neurotoxicity.
Therefore, we infected the cortical neurons with siRNA
DMT2IRE to decrease DMT12IRE expression to see whether
L-DOPA neurotoxicity was hence changed in these neurons. As
we expected, western blot analysis revealed a significant decrease
in the expression of DMT12IRE protein as well as iron content in
the neurons infected with siRNA DMT2IRE. The MTT assay
demonstrated that the viabilities in the neurons infected with
siRNA DMT2IRE were significantly higher than those in the
control neurons at all concentration points of L-DOPA we
Data are means6SEM (percentage of control) of four independent experiments. There were no significant differences in the levels of all four proteins
we investigated between the neurons treated with or without L-DOPA.
doi:10.1371/journal.pone.0004593.g009
Figure 10. Effects of siRNA DMT2IRE on DMT12IRE expression
and L-DOPA-induced neurontoxicity in cortical neurons. A and
B: Neurons were pre-incubated with siRNA DMT2IRE for 24 hours and
Western blots analysis was then performed (A: representative Western
blots of DMT12IRE and b-actin, and B: the relative values of DMT12IRE
protein in neurons infected with or without siRNA DMT2IRE). Data are
means6SEM (percentage of control) of four independent experiments
performed in triplicate. **P,0.01 vs. the control. C: Neurons were pre-
incubated with siRNA DMT2IRE for 24 hours and then treated with
different concentrations of L-DOPA (0, 1, 5, 10, 100, 200 mM) in
DMEM+5%FBS medium fro 16 hours. The neuronal viability was then
determined using an MTT assay. Data are the mean6SEM (percentage
of control) of four independent experiments performed in triplicate.
*P,0.05, ***P,0.001 vs. the corresponding controls.
doi:10.1371/journal.pone.0004593.g010
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DMT12IRE induced by siRNA DMT2IRE can decrease
neuronal iron accumulation and also L-DOPA neurotoxicity.
These further confirmed that DMT12IRE upregulation and the
increased DMT12IRE mediated iron influx play a key role in the
development of L-DOPA neurotoxicity in primary neurons.
DMT1 (DCT1 or NRAMP2), a widely expressed membrane
protein [27,28], is responsible for the uptake of a broad range of
divalent metal ions [27–29]. There are four DMT1 isoforms that
differ in their N- and C-termini arise from mRNA transcripts that
vary both at their 59-ends (starting in exon 1A or exon 1B) and at
their 39-ends giving rise to mRNAs containing (+) or lacking (2)
the 39-IRE [30]. The existence of DMT1 in the brain has been
well determined [17,31]. The functions of DMT1+IRE and
DMT12IRE have not been completely understood [32].
However, available data support the notion that DMT12IRE,
rather than DMT1+IRE, is the entity responsible for the
transmembrane transport of iron released from transferrin to the
early endosomal lumen [10,22]. Recent studies also inferred that
DMT12IRE is predominantly found in three compartments: the
plasma membrane, early/recycling endosomes, and the endoplas-
mic reticulum [22]. In the present study, we found that treatment
of neurons with different concentrations of L-DOPA also resulted
in a significantly dose-dependent increase in iron content, ferrous
iron uptake and the expression of DMT12IRE protein in cortical
neurons. It was also found that there is a significant correlational
relationship between the expression of DMT12IRE protein and
55Fe uptake (positively) in cortical neurons treated with different
concentrations of L-DOPA. These findings provide further
support to the notion that DMT12IRE, rather than DMT1+IRE,
is the entity responsible for iron transmembrane transport as well
as the role of DMT12IRE upregulation in L-DOPA neurotox-
icity.
In summary, in the present study we provided solid evidence for
the first time for the association of DMT12IRE with neurotoxicity
induced by L-DOPA. We concluded that upregulation of
DMT12IRE and then the increased DMT12IRE mediated iron
influx play a critical role in L-DOPA neurotoxicity in primary
cortical neurons. We also demonstrated for the first time that
ACM’s protection of cortical neurons from L-DOPA is at least
partly due to its ability to inhibit DMT12IRE expression and
ferrous iron uptake and its antioxidative activity which might be
due to the antioxidants supplied by astrocytes.
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